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Development of a new metastatic human breast
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Summary Xenografts originated from human tumours offer the most appropriate research material for in vivo experimental research.
However, primary human breast carcinomas are difficult to grow when transplanted in athymic mice: tumour take is less than 15%. Recently,
we have achieved 60% tumour take by injecting tumour cell suspensions mixed with Matrigel. Human breast xenografts originated from
primary breast carcinoma also frequently show the potential to metastasize spontaneously. In the present study, we generated a human
breast carcinoma xenograft line (UISO-BCA-NMT-18) that shows 100% tumorigenicity and 80-100% lung metastasis when transplanted s.c.
in athymic mice. We have studied in detail the characteristics of the xenograft and the patient's tumour from which the xenograft line
originated. Both the xenograft and the patient's tumour showed intense staining for mutant p53 nuclear protein, and high expression of U-PA,
PAI and u-PAR. In vivo growth of the xenograft is stimulated by exogenous supplementation of oestrogen. This xenograft is continuously
growing in mice and has shown 80-100% metastasis for the last three successive in vivo passages. This well-characterized, oestrogen-
responsive, metastatic breast carcinoma xenograft line will provide excellent research material for metastasis-related research.
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Metastasis of primary tumour to the visceral organs is a major
cause of cancer-associated mortality. Despite considerable
progress in the last decade in the areas of early detection and
surgical and chemotherapeutic management of clinically less
advanced cancers, treatment of metastatic disease is still a major
puzzle for oncologists. Research on metastatic disease has
severely suffered from lack of suitable experimental models.
Human tumour xenografts established from well-characterized
clinical material provide an important research tool for multidisci-
plinary research. In most cases, xenografts originated in vivo in
experimental animals preserve many of the original phenotypic,
biological and genotypic characteristics from which they originate
(Giovanella et al, 1989; Mehta et al, 1995a). However, human
breast carcinomas are difficult to grow in vitro in culture
(Nordquist et al, 1975; Engel and Young, 1978; Langlois et al,
1979; Whitehead et al, 1983; Chu et al, 1985; Mehta et al, 1992;
1995b ; Watanabe et al, 1992) or in vivo in experimental animals
(Sabestany et al, 1979; Shafie and Liotta, 1980; Rae-Venter and
Reid, 1980; Giovanella et al, 1985; Price and Zhang, 1990; Hurst
J, et al, 1993; Mehta et al, 1993), and they rarely metastasize when
transplanted subcutaneously (Shafie and Liotta, 1980; Price et al,
1990; Brunner et al, 1992; Mehta et al, 1993).
Recently, we obtained significant success in establishing
xenografts from primary breast carcinomas, and many of these
xenografts showed potential for spontaneous metastasis in athymic
mice when transplanted s.c. (Mehta et al, 1993). Initially, we used
Matrigel to develop xenografts from primary breast carcinomas
(Mehta et al, 1993; 1995a). Matrigel is a mixture of components
usually found in the extracellular matrix. The major components
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of Matrigel are laminin, collagen IV, heparan sulphate and
entactin. Matrigel not only increased the take rate ofhuman breast
carcinoma in athymic mice, but also promoted spontaneous metas-
tasis in approximately 40% of tumours (Mehta et al, 1993). In the
present study, we further explored the metastatic potential of a
xenograft by serial repetitive in vivo/in vitro propagation of a
human breast xenograft originated in mice. We have established a
human breast carcinoma xenograft line that is 80-100% metastatic
when transplanted s.c. in athymic mice.
MATERIAL AND METHODS
Procurement of human breast carcinoma
Primary human breast carcinoma was obtained from a 41-year-old
woman with confirmed diagnosis of primary human breast carci-
noma undergoing lumpectomy procedure. After surgical excision,
tumour tissue was immediately transported to the laboratory on
wet ice. Detailed information regarding histopathological details
of the tumour and the patient's disease status was obtained from
our tumour registry.
Enzymatic digestion of tumour
Tumour tissue was divided into small pieces, one of which was
fixed in 10% formalin and processed for histological and immuno-
histochemical analysis of various biomarkers. The remaining
tissue (approximately 0.2-0.3 g) was minced into small pieces and
mixed (1:10 volume) with a cocktail of enzymes composed of
0.002% deoxyribose nuclease type 1 (Sigma, St Louis, MO, USA),
0.1% collagenase (United States Biochemical Corporation,
Cleveland, OH, USA) and 0.01% hyaluronidase type V (Sigma,
St Louis, MO, USA) in Hanks' balanced salt solution (HBSS,
Biologos, Naperville, IL, USA), then incubated overnight at room
temperature. At the end of incubation, enzyme-digested tissue
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Figure 1 Patient's original tumour. (A) Histology of the tumour; (B) mutant type p53 protein; (C) immunohistochemical detection of oestrogen receptor;
(D) immunohistochemical detection of progesterone receptor; (E) nm23 protein; (F) cathepsin D; (G) Her-2/neu; (H) urokinase-type plasminogen activator;
(I) plasminogen activator receptor; (J) plasminogen activator inhibitor-1
suspension was centrifuged, and the tissue pellet was rinsed with
HBSS then suspended in HBSS/Matrigel mixture (1:1 volume)
(Collaborative Biomedical Products, Becton Dickinson Labware,
Bedford, MA, USA).
The tumour suspension was injected into the mammary fat pad
of 3- to 4-week-old female athymic (Balb/c) mice (Frederick
Cancer Research Facility, Frederick, MD, USA). Animals were
observed for development ofa palpable tumour; ifa tumour devel-
oped the tumour size (cm) was measured in three different planes
as height (h), width (w) and depth (d), using vernier calipers.
Tumour volume (cm3) was calculated using the formula
h x w x d x n/6 = cm3. For this study, the tumour doubling time
was calculated as the number ofdays required during the exponen-
tial growth phase for the tumour to grow from x volume to 2x
volume. The tumour latency period is the time (days) required for
the tumour to show apparent sustained increase in volume from the
initial volume ofinjected suspension or xenograft.
Animals were killed if they became moribund, had necrosis in
the tumour, or if the tumour volume reached > 2.5 cm' in volume.
All animals at termination were examined for metastatic lesions
in the visceral organs. Suspected lesions were processed for
histopathological examinations. The tumour that developed at the
inoculation site was divided into small pieces and processed for
histological studies, further in vivo propagation and studies of
various biochemical and immunohistochemical biomarkers.
Serial in vivo processing of human tumour xenograft in
athymic mice
The xenograft developed at the original inoculation site was
divided into small pieces and then trocared s.c. into athymic mice.
Matrigel was not used for serial transplantation of xenografts.
Tumour that developed during each serial passage was processed
British Journal ofCancer (1998) 77(4), 595-604 0 Cancer Research Campaign 1998598 RR Mehta etal
for histology and lactose denydrogenase (LDH) isoenzyme pattern
to confirm human origin ofthe xenograft.
Effect of low-dose oestrogen on in vivo growth of
xenografts
To determine the effect of oestrogen on the growth of xenografts,
xenografts were transplanted s.c. in the dorsal flank of3- to 4-week-
old athymic mice. Animals received a s.c. oestradiol-17f (0.1 mg
per animal)-containing pellet (Innovative Research, Toledo, OH,
USA) or placebo pellet. The growth of xenografts was monitored
periodically as described above.
Development of a metastatic tumour line by
in vivo/in vitro propagation of metastatic lesion
The xenografts were serially passaged in vivo in athymic mice as
mentioned above. If animals showed tumour metastasis in the
lung, metastatic tumour was transplanted s.c. into 4- to 6-week-old
female athymic mice. The tumour that developed at the subcuta-
neous site was passaged twice in vivo then cultured in vitro, and
A B
cells growing in vitro were mixed with Matrigel and then injected
into mice again. Tumour that developed from the cultured cells
was further passaged in vivo.
LDH isoenzyme analysis
LDH isoenzyme pattern in human breast xenograft developed in
mice was examined using the kits obtained from Corning
Scientific Products, Corning, NY, USA. Known human cell lines
were included as controls in each analysis.
Immunohistochemical analyses of various proteins
Immunohistochemical analyses of various protein biomarkers in
the original breast tumour and in the xenograft developed in mice
were performed by the indirect immunoperoxidase method, with
a labelled streptavidin-biotin complex kit (Dako Corporation,
Carpinteria, CA, USA). In brief, 4- to 5-jm-thick sections of
formalin-fixed paraffin-embedded tissues were mounted on
frosted microslides, and sections were deparaffinized in xylene
and rehydrated by processing through a graded series of alcohol
C
Figure 2 Light microscopic examination of human breast carcinoma UISO-BCA-NMT-18; (A) Xenograft from in vivo passage 1; (B) xenograft from passage 2;
(C) xenograft from passage 7.
A B
Figure 3 Immunohistochemical detection of (A) p53 protein and (B) Her-2/neu in UISO-BCA-NMT-18 xenograft
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Figure 4 (A and B) Western blot analyses of Her-2/neu and nm-23 in
UISO-BCA-NMT-18 xenograft (at passage 2/3) extract. Arrow shows protein
band of interest. M, Molecular weight markers
(100-0%). The tissue sections were rinsed in phosphate-buffered
saline (PBS) and then microwaved three times for 5 min in citrate
buffer (c-neu, Cathepsin) or in 6 M urea (p53) at 80% power. For
U-PA, PAI-I and UPAR studies, rehydrated tissue sections were
incubated for 30 min in 0.1% trypsin at 370C. The sections were
extensively washed with PBS.
To block non-specific binding, sections were incubated at room
temperature in 5% non-fatdry milkfor 10 min. Tissue sections were
rinsed in PBS and then incubated at 40C overnight in the moisture
chambers with appropriate diluted specific primary antibody. Tissue
that had been incubated with mouse IgG (5 jig ml-i) served as an
experimental control. At the end of the incubation, sections were
extensively rinsed in PBS, then incubated with biotinylated anti-
mouse/anti-rabbit link antibody for 10 min and with peroxidase-
conjugated streptavidin for 10 min. Staining was visualized using
3-amino 9-ethyl carbazole (AEC) or 3,3'-diaminobenzidine as
chromogen (Biogenex, San Ramon, CA, USA). Tissues were
A B
counterstained with haematoxylin. The tissue sections were
mounted in aqueous mounting medium. Primary antibodies
were obtained from different suppliers. Antibodies for oestrogen
receptor-progesterone receptor (ER/PR) were purchased from
Abbott Laboratories, Lake Forest, IL, USA; p53 and Her-2/neu
(Oncogene Science, Uniondale, NY, USA), nm-23 and cathepsin D
from Neomarkers (Fremont, CA, USA); U-PA, UPAR andPAIfrom
American Diagnostics (Greenwich, CT, USA).
Western blot analyses
Western blot analyses of nm23 and Her-2/neu proteins were
performed according to the method reported previously (Mehta et
al, 1995b). In brief, cells were washed with PBS and lysed in Tris
buffer, pH 6.8, containing 10% glycerol, 5% j-mercaptoethanol,
3% sodium dodecyl sulphate (SDS), 0.02% bromophenol blue,
1 mM phenylmethylsulphonyl fluoride, 5 mM EDTA, 10gg ml-'
aprotinin, and 1 ,ug ml-' DNAase. Cell lysis was performed at
37°C for 30 min. Proteins in the lysates were separated on 7.5%
SDS-polyacrylamide gel by electrophoresis. Proteins were elec-
troblotted to immunobilon paper overnight. The membrane was
incubated with primary antibody (1 jig ml-') at room temperature
for 1 h, washed with buffer, then incubated with goat anti-mouse
alkaline phosphatase. Specific immunoreactivity was visualized
using fuchsin as a chromogen.
RESULTS
Characteristics of human breast carcinoma
Histopathologically, the original patient's tumour was classified as
infiltrating ductal carcinoma ofthe breast (Figure IA). At the time
of surgery, no evidence of disease having spread to the axillary
lymph nodes was reported. The tumour was immunohistochemi-
cally positive for ER and PR and strongly positive for p53 and
intensely stained for nm23. The tumour showed weak to moderate
cytoplasmic staining for cathepsin D, strong cell membrane-
associated staining for PAI, U-PAR and U-PA. The tumour showed
strong immunoreactivity to Her-2/neu antibody (mouse mono-
clonal antibody against a specific peptide sequence from the
C
Figure 5 Immunohistochemical detection of (A) U-PA, (B) U-PAl and (C) UPAR in UISO-NMT-BCA-18 xenograft
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Figure 6 Growth of UISO-BCA-NMT-18 xenograft in athymic mice during
serial in vivo propagation. Number in parenthesis indicates passage number
in vivo. Number of animals at each passage varied between 2 and 5,
depending on the availability of xenograft material available. Data represent
mean tumour volume value obtained in the number of animals used for that
passage
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Figure 7 In vivo growth pattern of metastaic xenograft line. Data represent
mean tumour volume obtained in a group of five animals that received
xenograft transplant from the same tumour. Met-1, Met-2, Met-3 indicates
metastatic passage number
carboxyl domain ofhuman Her-2 gene product); however, staining
was predominantly localized in the cell membrane (Figures lB-J).
Growth of human breast carcinoma transplanted into
athymic mice
The cell suspension injected into mice initially formed a small
palpable tumour nodule 17 days after inoculation. The tumour
nodule failed to show continued growth and remained as a small
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Figure 8 Growth of UISO-BCA-NMT-18 xenografts with low metastatic
potential in athymic mice
nodule for 60 days. The nodule was excised and retransplanted
into two mice; at this time, two out of two animals formed
tumours.
The tumour latency period in this passage was 20 days. The
tumour doubling time at passage 1 was between 5 and 8 days. The
tumour was hard and localized at the inoculation site. During
successive serial passaging, 100% tumour formation was observed
in animals. The xenografts at each in vivo passaging were
confirmed to have human origin by LDH isoenzyme assay (data
not shown).
Characterization of human breast xenograft
Light microscopy ofthe xenograft at passage 1 showed small clus-
ters of human breast carcinoma cells embedded in host stromal
tissue. At passage 2, cell clusters grew more compact and had
minimal presence of host stromal tissue elements. The xenograft
from which 100% lung metastasis was first observed (passage 7)
showed histopathology similar to that of the original patient's
tumour. The clusters of tumour cells were infiltrated in host
stromal tissue, and evidence was frequently observed of necrotic
tissue scattered throughout the tumour tissue. At this time, many
tumour cells were seen at the different phases of cell division
(Figure 2A-C).
Immunohistochemical analyses of various biomarkers were
performed on the xenograft at in vivo passages 2 and 3 (before
generating the metastatic line). Immunohistochemically, detectable
specific staining was observed against Her-2/neu, p53 (Figure
3A-B), and nm23 (data not shown). The presence of Her-2/neu
protein was furtherconfirmed by Western blot analysis ofxenograft
extract (Figure 4A). Because nm23 antibody used in the present
study cross-reacts with two different proteins (nm23-HI and nm23-
H2), weperformedWestern blotanalysis on xenograft lysate. On the
SDS gel using denaturing condition in the cytosolic extract, we
observed two specific proteins immunoreactive to nm23 antibody,
approximately molecular weight 17 000 and 18 000 representing
both nm23-H1 and nm23-H2 proteins (Figure 4B).
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Figure 9 Histology of representative metastatic lesions in lungs. Size and number of metastatic lesions varied from animal to animal
We failed to observe specific immunoreactivity to antibodies
against ER, PR or cathepsin D in the xenograft. We observed mild
to moderate membrane-associated staining in the xenograft for
U-PA, UPAI and UPAR (Figure 5A-C).
Development of metastatic human breast xenograft line
The growth pattern of the xenograft during passage 1-7 shows
that, at early passages, growth was initially slow; however, after
passage 5, growth was enhanced. Initially, during passages 1-4,
the tumour showed longer tumour latency time and failed to
achieve true exponential growth. After passage 5, the tumour
began to show increased growth between 13-20 days; tumour
doubling time was between 8 and 9 days (Figure 6). Human breast
xenograft serially transplanted for six passages in athymic mice
showed no evident metastasis to visceral sites at any passages.
However, in the seventh passage, one out ofthree animals had lung
metastasis. At this time, the lung lesion was transplanted s.c. in
one animal to expand the tumour material, and the tumour that
developed at the injection site was passaged in two animals. The
xenografts developed in these animals were minced, and a small
portion was cultured in vitro and the remaining tissues were
retransplanted in mice and serially passaged.
The cells growing in culture from xenograft were transplanted
s.c. in two animals. At this time, one out of two animals showed
metastatic tumour in the lung. The xenograft developed at the site
of inoculation from the later animal was transplanted into five
animals. All five animals developed tumours and attained experi-
mental growth phase within 20-25 days; the tumour doubling time
in these animals was between 10 and 12 days. All five animals
showed metastasis in the lung (Met-1). We excised the xenografts
growing at the inoculation site from this last group of animals and
transplanted them into 15 animals. All 15 animals had tumours
growing at the inoculation site (Met-2) within 17-20 days, and 13
out of 15 animals had lung metastasis. In the next transplantation
(Met-3) into the animals, lung metastasis was found in 13 out of 14
animals. Figure 7 shows in vivo growth of xenografts with >80%
metastatic potential in vivo.
The xenografts serially passaged (to passage 12) in vivo without
in vitro propagation were 100% tumorigenic and showed occa-
sional incidence (10-20%) oflung metastasis. Detailed analysis of
growth pattern showed that, in general, xenografts developed in
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Figure 10 Effect of oestrogen supplement on in vivo growth of UISO-BCA-
NMT-18 xenograft. The xenograft (Met-3) was minced into small pieces and
transplanted (without Matrigel) s.c. into the dorsal flank region of 4- to 6-
week-old female athymic mice. Animals were divided into two groups, each
group consisting of five animals: (a) receiving placebo pellet, and (b)
receiving oestradiol-173 (0.1 mg)-containing pellet. Data represent mean
tumour volume obtained in five animals. Animals were killed when animals in
control group appeared sick. At autopsy, all visceral organs were examined
for evidence of metastasis
these animals had a relatively longer tumour doubling time
(ranging between 15 and 18 days, mean tumour doubling time =
16.8 + 0.9 days) compared with those xenografts with higher
metastatic ability. Figure 8 shows the growth of xenografts during
serial in vivo transplantation.
Figure 9 shows representative metastatic lesions developed in
mice. The number and volume or size of metastatic tumours in the
lungs varied widely from animal to animal and in vivo passage to
passage. Occasionally, we observed multiple metastatic tumours in
both lungs; however, most animals had 1-2 lesions per lung.
Histologically, lesions formed in the lungs were identical to the
xenograft developed at the subcutaneous site.
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Growth response to exogenous oestrogen
To determine whether UISO-BCA-NMT-18 xenografts (Met-3)
have maintained functional ER, we determined the response of
exogenously supplemented oestradiol on growth of these tumours.
As shown in Figure 10, growth of xenografts transplanted without
Matrigel into athymic mice bearing oestradiol pellets (0.1 mg) was
significantly (P < 0.05) higher than those transplanted into control
animals with placebo pellets. Interestingly, at the termination of
the experiment, five out of five mice treated with placebo pellets
showed metastatic lesions in the lungs; however, zero out of five
animals treated with oestradiol showed lung metastasis.
DISCUSSION
Breast cancer is the most common cancer among women and the
second leading cause of cancer-related death in women. Although
significant progress has been made in the last decade for early
detection of tumours and treatment of clinically less advanced
carcinoma, management of advanced breast cancer has still not
improved. The process of metastasis is complex: it involves
cascades of various biochemical and molecular steps (Liotta et al,
1983; Nicolson, 1988). Factors associated with both the host tissue
and the malignant cells play crucial roles in the invasion and
metastasis of tumour cells (Boghaert et al, 1992; Lester and
McCarthy, 1992). Even though various investigators are engaged
in understanding the actual molecular and biological steps in the
process of metastasis, the exact mechanism of the process is still
not fully understood. In addition, research on evaluating new
antimetastatic drugs for breast cancer is severely hampered
because of the unavailability of suitable experimental models for
breast cancer metastasis.
For experimental research on metastatic disease, a reliable
experimental tool is necessary. At present, numerous breast carci-
noma cell lines established from primary solid human breast carci-
noma or from the metastatic pleural fluids are available for various
research (Nordquist et al, 1975; Engel and Young, 1978; Langlois
et al, 1979; Whitehead et al, 1983; Chu et al, 1985; Mehta et al,
1992; 1995b; Watanabe et al, 1992; Slooten et al, 1995); however,
only a limited number of these cell lines are tumorigenic in mice,
and only two to three of these cell lines show distant metastasis
when transplanted s.c. into athymic mice (Shafie and Liotta, 1980;
Price et al, 1990; Brunner et al, 1992; Mehta et al, 1993). In addi-
tion the incidence of metastasis in these cell lines varies in
different laboratories (Shafie and Liotta, 1980). Thus, establish-
ment of a well-characterized human breast carcinoma xenograft
line with highly tumorigenic and metastatic potential in experi-
mental animals is of great value in metastatic research.
In general, human breast carcinomas fail to grow when trans-
planted into athymic mice. The tumour take of human breast
tumours is generally about 6-15% (Shafie and Liotta, 1980; Mehta
et al, 1993). In our laboratory, tumour take is generally >60% when
enzymically digested tumours are injected into mice mixed with
Matrigel (Mehta et al, 1993; 1995a). Matrigel not only increased
tumour take but also enhanced tumour growth and facilitated spon-
taneous distant metastasis (Mehta et al, 1993). In the present study,
we have established a human breast carcinoma xenograft line from
a primary human breast carcinoma using Matrigel as described
previously (Mehta et al, 1993; Mehta et al, 1995a;).
To establish a xenograft in athymic mice, the original patient's
tumour was digested with a cocktail of enzymes, and the resulting
cell suspension was pelleted and mixed with Matrigel then
injected into athymic mice. Initially, during the first in vivo
passage, the tumour grew as a small nodule at the site of the orig-
inal tumour inoculation. However, in subsequent serial passaging,
100% of animals showed tumour growth at the site of the original
xenograft transplantation. During serial passaging, inconsistent
but occasional incidence of lung metastasis was observed in
animals, suggesting metastatic potential of the xenograft. We
expanded the metastatic tumour cells in the xenograft by in vivo
passaging of lung lesions. We further cultured the metastatic
tumour in vitro and then inoculated the culture in vivo. Further
continuous in vivo passaging of breast xenograft developed from a
metastatic lesion generated a xenograft line that is 80-100%
tumorigenic in athymic mice for the last three successive in vivo
passages. The xenografts continuously passaged in vivo without in
vitro exposure have maintained low metastatic potential. From our
results it is evident that during in vitro culturing of a xenograft
originating from a metastatic lesion, the selection ofhighly aggres-
sive and metastatic cells occurs.
It appears that, during serial in vivo passaging, gradual changes
in xenograft histopathology occurred. Initially, at passage 1, the
xenograft showed small clusters of cells embedded in host stromal
tissues. In passage 2 and thereafter, most ofthe tumour was packed
with malignant breast cells with minimal presence of the host
stromal tissue. In later passages, the xenograft histology appeared
to be similar to that of human breast tumour- that is tumour cells
were infiltrated in the host stroma as clusters of cells simulating
infiltrating ductal carcinoma histopathology.
The xenograft UISO-NMT-BCA- 18 preserved many pheno-
typic characteristics of the patient's tumour from which it origi-
nated. The original patient's tumour was positive for mutant type
p53, a tumour-suppressor nuclear phosphoprotein. The patient's
tumour also had high expression of U-PA, PAI and UPAR. All
these markers are associated with highly aggressive breast cancer
(Slamon et al, 1987; Berger et al, 1988; Clark and McGuire 1991;
Allred et al, 1992; Caleffi et al, 1994; Gasparini et al, 1994;
McDonald et al, 1995; Hamby et al, 1996). We observed intense
immunoreactivity against antibodies to human Her-2/neu in the
patient's tumour. A similar staining pattern was also evident in the
xenograft. We further confirmed the presence of overexpressed c-
erbB2 in xenografts using Western blot analysis. More recently,
two additional genes called nm23-1 and nm23-2 are thought to
influence the metastatic potential of malignant tumours
(McDonald et al, 1995; Hamby et al, 1996). Experimental
evidence suggests that altered expression of nm23-1 or nm23-2
protein is associated with increased metastatic potential
(McDonald et al, 1995; Hamby et al, 1996). The patient's original
tumour showed enhanced expression of nm23 protein immunohis-
tochemically. The antibody used in our assay detects both nm23-1
and nm23-2 proteins. Thus, enhanced nm23 expression observed
in the patient's tumour is probably the result of altered levels of
nm23-2 protein levels compared with nm23-1; using Western blot
analysis, we detected high levels of nm23-1 protein in the
xenograft at early passages. Similarly, U-PA, PAI and UPAR have
been shown to have prognostic significance (Janicke et al, 1993;
Bouchet et al, 1994; Duffy et al, 1994; Foekens et al, 1994;
Foekens et al, 1995). Thus, this xenograft line is ideal for evalu-
ating new chemotherapeutic agents that will effectively prevent
metastasis ofhighly aggressive tumours.
The patient's tumour had positive immunoreactivity for ER, PR
and cathepsin D. In the xenograft at passages 2 and 3, we failed to
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detect ER by immunohistochemical assay. However, increased
growth response to exogenously supplemented oestrogen observed
in later passages in the line with metastatic ability compared with
the placebo control group suggests that these tumour lines have
maintained functional ER status. Failure to detect ER in xenograft
tumours could be due to down-regulation of this protein by
endogenous ligands (in mice) of c-erbB2. Two different ligands,
gp3O and p75, have been shown to down-regulate in a dose-depen-
dent manner the expression of ER in ER positive BT-474 and
MCF-7 breast carcinoma cell lines in oestrogen-depleted medium
(Grunt et al, 1995). On the contrary, low levels of oestrogen (0.1-
1 nM) treatment to oestrogen-responsive MCF cells have been
reported to cause a rapid but sustained drop in Her-2/neu mRNA
(Read et al, 1990), suggesting that oestrogen has a differential
effect on the markers associated with tumour aggressiveness and
cell proliferation. Our results on in vivo growth and metastatic
behaviour of UISO-NMT-BCA-8 in mice in the presence/absence
of oestrogen are in agreement with those obtained in vitro in
human breast cancer cells by Read and associates (1990). In
athymic mice, UISO-BCA-NMT-18 showed increased growth by
oestradiol but showed inhibition of metastatic potential compared
with untreated controls. In this tumour line, down-regulation of
Her-2/neu expression by oestradiol may inhibit tumour metastasis.
Further detailed studies are currently in progress to understand the
mechanism of oestradiol action on various molecular markers
associated with breast carcinoma cell proliferation and metastasis.
In summary, the human breast xenograft reported in the present
study is ofgreat value for human breast cancer research. Currently,
for metastatic breast cancer research MDA-MB-231 and MDA-
MB-435 are widely used (Brunner et al, 1992; 1993). Both these
cell lines were originated from metastatic pleural effusion, are
highly tumorigenic, and have high metastatic potential. In addition,
both these cell lines have been reported to be ER-negative. To the
best of our knowledge, no reliable, highly metastatic ER-positive
cell line or xenograft line is available for research. In general, the
UISO-NMT-BCA-18 xenograft line differs from the existing
metastatic lines as it originated from primary human breast carci-
noma and is responsive to oestrogen. Thus, the addition of a well-
characterized ER-positive tumour line to an existing panel of
metastatic human breast carcinoma cell lines will provide a
valuable tool with which to study the role of various oestrogen-
regulated genes in metastasis ofhuman breast cancer.
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